It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
With over 60 molecules delivered into preclinical development, we bring deep insight into what makes a hit truly viable.
Our experience is built into every project from the start, helping you avoid costly mistakes and move forward with confidence.
Drug discovery is complex, costly, and full of risk. Choosing the wrong hit can lead to delays, unexpected challenges, and wasted investments. That’s why we prioritize the hit-to-lead stage where smart decisions save time and money later.
At Sygnature Discovery, we assess risk early and build strategies to overcome it. Our goal is to deliver compounds that move confidently into lead optimization, increasing your chances of clinical success and patient impact.
Our Expertise in Hit to Lead Techniques
Sygnature Discovery has a well-established infrastructure and expertise to conduct effective hit-to-lead projects in a timely manner.
High Throughput Chemistry
Our automated platforms, combined with Direct-to-Biology and Direct-to-Crystallography approaches, enable fast and efficient hit expansion. We improve potency, selectivity, and DMPK while enhancing drug-like properties to support downstream development.
We use in-silico profiling to guide synthetic strategies and enable scaffold core-hopping, generating new hit series with improved properties and better development potential.
Core Hopping
Powered by generative AI and deep medicinal chemistry expertise, our core-hopping workflows accelerate scaffold redesign and synthetic route planning, which can generate novel hit series with enhanced characteristics.
Appropriate Screening Cascades
Our teams identify liabilities early using tailored screening cascades. We propose alternative structures that retain key interactions while improving physicochemical properties and metabolic stability.
in vitro ADME
We offer a wide range of in vitro ADME assays to profile hits and assess liabilities early, supporting smarter decisions and reducing downstream risk.
Our hit to lead strategies are designed to move your project quickly toward in vivo proof of concept and deliver high-quality molecules ready for lead optimization.
Right Target, Right Approach
Tailored workflows for your target, modality and dosing route, ensuring compounds are fit for purpose.
Efficient Workplans
Integrated medicinal chemistry, bioassay development, and in silico hypothesis testing deliver candidates ready for optimization.
Early Risk Assessment
Rapid evaluations of in vitro and in vivo DMPK properties helps identify risks early and guide expert intervention.
Why Choose Sygnature Discovery for Hit to Lead Support?
We know what it takes to move a molecule from bench to clinic. Our expert teams apply that knowledge early to de-risk your program and accelerate progress.
With no internal pipeline, our full focus is on your goals. We combine scientific integrity, momentum, and global collaboration to deliver exceptional outcomes, helping you move faster, smarter, and with greater confidence.
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Discover CHARMED, Sygnature’s innovative PROTAC platform, showcasing rapid degrader identification demonstrated with SHP2 as a model oncology target. Explore our advancements in protein degradation.
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Target Identification & Validation
Combining AI-driven insights, expert guidance, and rigorous lab validation to select and confirm targets for successful drug discovery.
Delivering validated, high-quality hits through integrated technologies, strategic insight, and expert collaboration to advance your program with confidence.
Transforming early leads into clinical-quality candidates through integrated expertise, rapid decision-making, and optimized strategies for safety, potency, and exposure.
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.
Automated high-throughput chemistry delivering rapid, high-quality compound libraries enabling efficient SAR exploration and faster progression from concept to candidate.
